- Home
- FSEA vs BLRX Comparison
FSEA vs BLRX Comparison
Compare FSEA & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSEA
- BLRX
- Stock Information
- Founded
- FSEA 1890
- BLRX 2003
- Country
- FSEA United States
- BLRX Israel
- Employees
- FSEA N/A
- BLRX N/A
- Industry
- FSEA Savings Institutions
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- FSEA Finance
- BLRX Health Care
- Exchange
- FSEA Nasdaq
- BLRX Nasdaq
- Market Cap
- FSEA 44.0M
- BLRX 36.0M
- IPO Year
- FSEA N/A
- BLRX 2011
- Fundamental
- Price
- FSEA $9.14
- BLRX $0.48
- Analyst Decision
- FSEA
- BLRX Strong Buy
- Analyst Count
- FSEA 0
- BLRX 2
- Target Price
- FSEA N/A
- BLRX $11.50
- AVG Volume (30 Days)
- FSEA 6.2K
- BLRX 407.5K
- Earning Date
- FSEA 11-08-2024
- BLRX 11-29-2024
- Dividend Yield
- FSEA N/A
- BLRX N/A
- EPS Growth
- FSEA N/A
- BLRX N/A
- EPS
- FSEA N/A
- BLRX N/A
- Revenue
- FSEA $11,390,000.00
- BLRX $17,048,000.00
- Revenue This Year
- FSEA N/A
- BLRX N/A
- Revenue Next Year
- FSEA N/A
- BLRX N/A
- P/E Ratio
- FSEA N/A
- BLRX N/A
- Revenue Growth
- FSEA N/A
- BLRX N/A
- 52 Week Low
- FSEA $6.25
- BLRX $0.39
- 52 Week High
- FSEA $9.49
- BLRX $1.93
- Technical
- Relative Strength Index (RSI)
- FSEA 50.72
- BLRX 53.32
- Support Level
- FSEA $9.00
- BLRX $0.40
- Resistance Level
- FSEA $9.35
- BLRX $0.46
- Average True Range (ATR)
- FSEA 0.12
- BLRX 0.03
- MACD
- FSEA 0.00
- BLRX 0.01
- Stochastic Oscillator
- FSEA 40.00
- BLRX 94.50
About FSEA First Seacoast Bancorp Inc.
First Seacoast Bancorp Inc is a savings and loan holding company. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank, in one-to-four-family residential real estate loans, commercial real estate, and multi-family real estate loans, acquisition, development and land loans, commercial and industrial loans, home equity loans and lines of credit and consumer loans. The company generates revenue from financial instruments, such as loans, letters of credit, and investment securities, as well as revenue related to mortgage servicing activities and bank-owned life insurance.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.